The FDA has approved Amgen‘s Vectibix following priority review. Vectibix is the first entirely human monoclonal antibody for the treatment of patients with epidermal growth factor receptor- (EGFr) expressing metastatic colorectal cancer after disease progression on or following fluoropyrimidine-, oxaliplatin-, and irinotecan- containing chemotherapy regimens. The approval of Vectibix was based on a progression-free survival endpoint. Vectibix is the first anti-EGFr antibody shown to si...